Constellation Pharmaceuticals Inc
Constellation Pharmaceuticals — Investor Presentation (November 2018)
40 slides from Constellation Pharmaceuticals's investor presentation, Nov 9, 2018
Slide 1: Corporate Overview November 2018
Developing Treatments Targeting Epigenetic Mechanisms in Tumor and Immune Cells for Cancer Patients Corporate Overview November 2018 Exhibit 99.2
Slide 2: Forward-looking statements
This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regarding the development status of the Company’s product candidates, the anticipated benefits of
Slide 3: Constellation Highlights
Multiple Lead Clinical Programs CPI-1205 (EZH2) and CPI-0610 (BET) Encouraging Preliminary Clinical Data Prostate cancer, solid tumors, and myelofibrosis Near-Term Milestones Proof-of-concept determination for each lead program expected in mid-2019 Expanding the EZH2 Opportunity Second-generation EZ
Slide 4: Targeting epigenetic mechanisms: writers, erasers, readers
Instructions for Genetic Code Tumor Cells MDSC NK Cell T Cell Focused on Three Distinct Classes That Chemically Modify Chromatin Tumor Microenvironment Target Transcriptional Networks That Result in Cell Death Re-program Immune Cells to Overcome Resistance to Cancer Immunotherapies Transcriptional C
Slide 5: Multiple Near-Term Opportunities for Success
Multiple Near-Term Opportunities for Success Product Candidates Indications Preclinical Phase 1 Phase 2 Phase 3 Next Milestone EZH2 Franchise CPI-1205 mCRPC Proof of Concept Mid 2019 CPI-1205 Solid Tumors Safety and RP2D Early 2019 CPI-0209 (2nd Gen) Solid Tumors / Heme Malignancies Initiate Phase 1
Slide 6: CPI-1205 and CPI-0209 EZH2 Franchise
CPI-1205 and CPI-0209 EZH2 Franchise
Slide 7: EZH2 Writer Activity Suppresses Gene Transcription
EZH2 “Writer” Activity Suppresses Gene Transcription EZH2 Inhibition Offers Broad Therapeutic Potential Polycomb Repressive Complex 2 (PRC2)… … Methylates Histone H3 at Lysine 27 (K27) EZH2 SUPPRESSED TRANSCRIPTION Acquired Drug Resistance: EZH2 mediates gene silencing that diminishes response to ex
Slide 8: Model for EZH2 Role in Prostate Cancer
*Signature of H3K27me3-occupied EZH2 target genes repressed in metastatic relative to clinically localized prostate cancer and benign prostate tissue Model for EZH2 Role in Prostate Cancer EZH2 Gene Signature* Predicts Outcomes in Prostate Cancer Yu et al., Cancer Research 2007 Pro-tumor Signaling E
Slide 9: EZH2 Synergy with Androgen Receptor Signaling
Evidence of EZH2 Synergy with Androgen Receptor Signaling (ARS) CPI-1205 Enhances the Gene Signature of Enzalutamide in Prostate Cancer Cells CPI-1205 is Active as Monotherapy and Synergistic with Enzalutamide in Killing Prostate Cancer Cells Enzalu- tamide CPI- 1205 Combo Theoretical concentration
Slide 10: Current Treatment Paradigm in mCRPC
*ASCO 2018 Poster Khalaf, et al (Kim Chi Lab) Current Treatment Paradigm in mCRPC Metastatic Castration-Resistant Prostate Cancer (30,000–50,000 Diagnosed Annually) 1st Line Abiraterone or Enzalutamide 2nd Line Enzalutamide or Abiraterone 3rd Line Chemotherapy or Palliative Care 60–80% PSA Response
Slide 11: ProSTAR Trial Design
Second-Line Trial After Ineffective Treatment with Androgen Receptor Signaling (ARS) Inhibitor ProSTAR Trial Design Enzalutamide + CPI-1205 (Prior Abiraterone Progression) Abiraterone + CPI-1205 (Prior Enzalutamide Progression) Selected ARS Inhibitor + CPI-1205 (Progressed on Different ARS Inhibitor
Slide 12: ProSTAR Trial: Treatment Duration
Data cutoff May 25, 2018 *Continued on CPI-1205 monotherapy after cycle 1 Discontinued Treatment ProSTAR Trial: Treatment Duration 2 of 6 evaluable patients achieved PSA80 2 of 4 evaluable patients with CTCs achieved CTC reduction of > 30% 2 of 2 evaluable patients had resolution of metastatic disea
Slide 13: Resolution of Bone Metastases
*Continued on CPI-1205 monotherapy after cycle 1 Resolution of Bone Metastases Baseline Cycle 4 Day 1 CPI-1205 + Enzalutamide*
Slide 14: Objective Response by CT Scan
Objective Response by CT Scan February 2018 Baseline: December 2017 CPI-1205 + Enzalutamide
Slide 15: Significant PSA Reduction in Compassionate-Use Patient
Significant PSA Reduction in Heavily Pre-Treated and Refractory Patient Experience with a Compassionate-Use Patient 3,000 2,500 2,000 1,500 1,000 500 12 agents prior to CPI-1205, including second-generation androgen inhibitors, chemotherapy, PARP inhibitors, tyrosine kinase inhibitors, checkpoint in
Slide 16: CPI-0209: Second-Generation EZH2 Inhibitor
Tazemetostat CPI-0209 Once-Daily Treatment Resulted in Rapid, Complete, and Durable Tumor Regression CPI-0209: Second-Generation EZH2 Inhibitor CPI-0209 May Provide More Comprehensive EZH2 Coverage, Expanding Addressable Populations Lymphoma Xenograft Mouse Model Vehicle Tazemetostat, 160 mg/kg oral
Slide 17: CPI-0610 BET Inhibitor
CPI-0610 BET Inhibitor
Slide 18: Control of Key Pathways: Opportunity in Myelofibrosis
Control of Key Immune, Fibrotic, and Oncogenic Pathways Leads to Opportunity in Myelofibrosis (MF) BET Family of Proteins … Enhancer TSS BRD4 Transcription Factor … Fibrosis TGF-β target genes Immune Signaling NF-κB target genes Cancer Genetics MYC, BCL2
Slide 19: CPI-0610 Background
Treated 138 patients in Phase 1 trials of hematologic malignancies Multiple objective responses observed at a range of doses below the maximum tolerated dose Demonstrated favorable PK/PD profile Activity seen in the context of NF-κB-driven diseases ABC-DLBCL (Phase 1) 7 patients at relevant doses: 1
Slide 20: Rationale for BET Role in Myelofibrosis
BET Inhibition May Block Proliferation of Inflammatory Bone Marrow Cells and Synergize with JAK Inhibition Rationale for BET Role in Myelofibrosis BET Signaling Megakaryocyte Differentiation/Proliferation Pro-Inflammatory Cytokines (e.g., IL-8) JAK/STAT Signaling STAT STAT Cytoplasm Nucleus NF-kB Ta
Slide 21: Rationale for BET's Role in Myelofibrosis: Data
Constellation Pharmaceuticals Data Rationale for BET’s Role in Myelofibrosis CPI-0610 vs DMSO 25 nM 100 nM 400 nM Vehicle 1–2+ JQ1 (BETi) 1+ Ruxolitinib 1+ Combo 0 Inhibition of Megakaryocyte Differentiation in vitro BET Inhibitor + Ruxolitinib Led to Synergistic Reduction in Spleen Volume (Left) an
Slide 22: Myelofibrosis (MF) Background
Myeloproliferative neoplasm characterized by scarring (fibrosis) of the bone marrow caused by impaired hematopoiesis 17,000–20,000 diagnosed patients in US* Three main features: Symptoms of organomegaly (spleen and liver) Symptoms of systemic inflammation Anemia and thrombocytopenia Only approved th
Slide 23: Underserved MF Patient Population
Standard of care and the only approved drug treatment is ruxolitinib (Jakafi) Significant improvement in splenomegaly and symptoms, but limited evidence of disease-modifying effect 30–40% of patients respond adequately in clinical trials* Thrombocytopenia and/or anemia may lead to patients receiving
Slide 24: Need for New Disease-Modifying Treatments in MF
Inadequate response in 1L disease No approved therapy in 2L disease Patients burdened by increased reliance on transfusions Need for new disease-modifying therapies that increase response rate and improve hematopoietic function Need for New Disease-Modifying Treatments in MF *Source: Mesa, R., et al
Slide 25: Rationale for MANIFEST Design
First-line arm in combination with ruxolitinib aims to address inadequate response to ruxolitinib alone in spleen volume reduction, patient-reported symptom improvement, and other factors, including lack of disease-modifying effects of ruxolitinib Second-line arm aims to provide a treatment option,
Slide 26: Development Plan to Expand the CPI-0610 Opportunity
* Cohort 3 will enroll anemic patients, pivotal trial plans would include all comers Robust Development Plan to Expand the CPI-0610 Opportunity MANIFEST: Expanded Phase 2 Trial in MF Cohort 1A: 2L Transfusion Dependent (TD) n = up to 16 Cohort 1B: 2L Non-TD n = up to 25 Cohort 2A: 2L Transfusion Dep
Slide 27: MANIFEST: First Four Patients Treated
Best Spleen Response Reduced spleen size Symptom improvement One patient with thrombocytosis and one patient transfusion-dependent at baseline—both resolved Spleen Size Reduced in All Patients as Measured by MRI MANIFEST: First Four Patients Treated Data cutoff May 25, 2018 Ongoing > 10 months Ongoi
Slide 28: Improved Hematopoiesis on CPI-0610
Data cutoff May 25, 2018 Patient Achieved Transfusion Independence and Improved Platelet Count Improved Hematopoiesis on CPI-0610 Patient treated with CPI-0610 + ruxolitinib combination therapy Transfusions No Transfusions for >24 Weeks 4 wks 4 wks 4 wks 6 wks
Slide 29: Hemoglobin Levels Increased in First Four Patients
Data cutoff May 25, 2018 Hemoglobin Levels Increased in First Four Patients Treated Improved Hematopoiesis on CPI-0610
Slide 30: CPI-0610 Summary
CPI-0610 has demonstrated clinical activity in early clinical trials with NF-κB-driven cancers, including MF, suggesting CPI-0610 may be differentiated among BET inhibitors Preliminary clinical data in 2L myelofibrosis show improvements in spleen volume, symptom scores, hematopoiesis, and transfusio
Slide 31: Discovery Platform Fueling the Pipeline
Discovery Platform Fueling the Pipeline Innate Adaptive Normalize aberrant gene expression within cancer cells Increase tumor immunogenicity Re-program immune cells to overcome resistance to cancer immunotherapies Tumor Cells Immune Cells Discovery Programs Targeting Epigenetic Regulators on the Tum
Slide 32: Financial Strength
Financial Strength
Slide 33: Potential Value Creation Catalysts
Potential Value Creation Catalysts 2019 2018 Early 2018 Complete crossover financing Expand enrollment in ProSTAR Initiate ORIOn-E Select 2nd generation EZH2 inhibitor candidate (CPI-0209) Late 2018 Additional active sites in US, Canada / EU for CPI-0610 in myelofibrosis Initiate Phase 2 portion of
Slide 34: Strong Cash Position
Post-IPO cash expected to fund operations into 2020, including: Ongoing clinical trials to determine proof of concept for CPI-1205 and CPI-0610 Continued advancement of CPI-0209 Ongoing support for robust discovery/preclinical Oversubscribed crossover financing round in April raised $100 million fro
Slide 35: Management Team
Management Team Jigar Raythatha President and CEO Emma Reeve Chief Financial Officer Adrian Senderowicz, M.D. Chief Medical Officer Brad Prosek SVP, Corporate Development Robert Sims, PhD SVP, Research Patrick Trojer, PhD SVP, Translational Sciences Karen Valentine Chief Legal Officer, General Couns
Slide 36: Appendix
Appendix
Slide 37: Expanding EZH2 Opportunity
Expanding EZH2 Opportunity Mutant Follicular Lymphoma Solid Tumors in Combination with Standard of Care in Both Tumors and Immune Cells mCRPC Anti-PD-1 Progressors Solid Tumors and/or Heme Malignancies Genetics That Validate EZH2 Enhance Effectiveness of Standard of Care Comprehensive Target Engagem
Slide 38: CPI-1205 Improves Anti-Tumor Immune Activity
CPI-1205 Improves Anti-Tumor Immune Activity Pam Sharma June 2018 Jeff Bluestone and Michel DuPage June 2018 Synergistic Impact with Checkpoint Inhibitor in Preclinical Model MB49
Slide 39: CPI-1205 Checkpoint Combination Study Design
Enrolling All Comers in Solid Tumors CPI-1205 Checkpoint Combination Study Design Ipilimumab + CPI-1205 (Prior Anti-PD-(L)1) Pembrolizumab + CPI-1205 (Prior Anti-PD-(L)1) Expansion Cohorts Checkpoint Inhibitor + CPI-1205 Phase 1b Phase 2 Testing Biomarkers for Patient Enrichment RP2D
Slide 40: ORIOn-E Summary
1 PR + 3 SD out of 6 patients treated with CPI-1205 + ipilimumab 42% Reduction in Tumor Volume from Baseline Phase 1b/2 All Comers Solid Tumors Progressed on Anti-PD-(L)1 ORIOn-E Summary as of May 25, 2018 Clinical Activity Observed in Anti-PD-1 Progressors Discontinued Treatment Stable Disease Part
Constellation Pharmaceuticals — Investor Presentation (November 2018) on 6ix